secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001628280-26-006460
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share
----------------------------------------------------------

- Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.
- Aggregate gross proceeds of $172.5 million before underwriting discounts and offering expenses.
- Common stock began trading on Nasdaq Global Select Market under ticker SGP on February 6, 2026.
- Habib Dable appointed to board as Class I director and to compensation committee; receives standard director compensation and option grant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/0001628280-26-006460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/spyglassclosing8-k.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-006460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer